Your search returned 1590 results.

Results
	1141.	The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. [electronic resource] by Zanini, Elisa Louis, Louay S Antony, Jane Karali, Evdoxia Okon, Imoh S McKie, Arthur B Vaughan, Sebastian El-Bahrawy, Mona Stebbing, Justin Recchi, Chiara Gabra, Hani Producer: 20180717 In: Molecular cancer therapeutics vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1142.	Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005. [electronic resource] Producer: 20060126 In: Clinical breast cancer vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1143.	Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. [electronic resource] by Kondo, Norio Tsukuda, Mamoru Ishiguro, Yukari Kimura, Machiko Fujita, Kyoko Sakakibara, Atsuko Takahashi, Hideaki Toth, Gabor Matsuda, Hideki Producer: 20100614 In: Oncology reports vol. 23 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1144.	Promising newer molecular-targeted therapies in head and neck cancer. [electronic resource] by Wang, Lili X Agulnik, Mark Producer: 20090126 In: Drugs vol. 68 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1145.	Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. [electronic resource] by Carloni, Silvia Fabbri, Francesco Brigliadori, Giovanni Ulivi, Paola Silvestrini, Rosella Amadori, Dino Zoli, Wainer Producer: 20100805 In: Current cancer drug targets vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1146.	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. [electronic resource] by Capri, G Chang, J Chen, S-C Conte, P Cwiertka, K Jerusalem, G Jiang, Z Johnston, S Kaufman, B Link, J Ro, J Schütte, J Oliva, C Parikh, R Preston, A Rosenlund, J Selzer, M Zembryki, D De Placido, S Producer: 20100513 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1147.	[Breast cancer and Her-2]. [electronic resource] by Hatake, Kiyohiko Producer: 20070904 In: Nihon rinsho. Japanese journal of clinical medicine vol. 65 Suppl 6 Availability: No items available. Save to lists Add to cart (remove)
	1148.	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. [electronic resource] by Agulnik, Mark Cohen, Ezra W E Cohen, Roger B Chen, Eric X Vokes, Everett E Hotte, Sebastien J Winquist, Eric Laurie, Scott Hayes, D Neil Dancey, Janet E Brown, Shirley Pond, Gregory R Lorimer, Ian Daneshmand, Manijeh Ho, James Tsao, Ming-Sound Siu, Lillian L Producer: 20070911 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1149.	Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells. [electronic resource] by Ma, Chuandong Zuo, Wenshu Wang, Xingwu Wei, Ling Guo, Qian Song, Xianrang Producer: 20130613 In: Oncology reports vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1150.	Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. [electronic resource] by Itamochi, Hiroaki Kato, Misaki Nishimura, Mayumi Oishi, Tetsuro Shimada, Muneaki Sato, Shinya Naniwa, Jun Sato, Seiya Nonaka, Michiko Kudoh, Akiko Terakawa, Naoki Kigawa, Junzo Harada, Tasuku Producer: 20130418 In: Human cell vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1151.	Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. [electronic resource] by Fedele, Carmine Riccio, Gennaro Malara, Angela Eliana D'Alessio, Giuseppe De Lorenzo, Claudia Producer: 20121123 In: Breast cancer research and treatment vol. 134 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1152.	Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. [electronic resource] by Kroep, J R Linn, S C Boven, E Bloemendal, H J Baas, J Mandjes, I A M van den Bosch, J Smit, W M de Graaf, H Schröder, C P Vermeulen, G J Hop, W C J Nortier, J W R Producer: 20110308 In: The Netherlands journal of medicine vol. 68 Availability: No items available. Save to lists Add to cart (remove)
	1153.	Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. [electronic resource] by Crown, J Kennedy, M J Tresca, P Marty, M Espie, M Burris, H A DeSilvio, M Lau, M R Kothari, D Koch, K M Diéras, V Producer: 20140422 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1154.	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. [electronic resource] by Rimawi, Mothaffar F Mayer, Ingrid A Forero, Andres Nanda, Rita Goetz, Matthew P Rodriguez, Angel A Pavlick, Anne C Wang, Tao Hilsenbeck, Susan G Gutierrez, Carolina Schiff, Rachel Osborne, C Kent Chang, Jenny C Producer: 20130701 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 31 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1155.	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. [electronic resource] by Liu, Y J Shen, D Yin, X Gavine, P Zhang, T Su, X Zhan, P Xu, Y Lv, J Qian, J Liu, C Sun, Y Qian, Z Zhang, J Gu, Y Ni, X Producer: 20140623 In: British journal of cancer vol. 110 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1156.	Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. [electronic resource] by Yeh, Elizabeth S Abt, Melissa A Hill, Elizabeth G Producer: 20150928 In: Breast cancer research and treatment vol. 149 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1157.	Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). [electronic resource] by Burstein, Harold J Cirrincione, Constance T Barry, William T Chew, Helen K Tolaney, Sara M Lake, Diana E Ma, Cynthia Blackwell, Kimberly L Winer, Eric P Hudis, Clifford A Producer: 20150310 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 32 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1158.	Gene isoforms as expression-based biomarkers predictive of drug response in vitro. [electronic resource] by Safikhani, Zhaleh Smirnov, Petr Thu, Kelsie L Silvester, Jennifer El-Hachem, Nehme Quevedo, Rene Lupien, Mathieu Mak, Tak W Cescon, David Haibe-Kains, Benjamin Producer: 20180927 In: Nature communications vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1159.	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. [electronic resource] by Llombart-Cussac, Antonio Cortés, Javier Paré, Laia Galván, Patricia Bermejo, Begoña Martínez, Noelia Vidal, Maria Pernas, Sònia López, Rafael Muñoz, Montserrat Nuciforo, Paolo Morales, Serafín Oliveira, Mafalda de la Peña, Lorena Peláez, Alexandra Prat, Aleix Producer: 20170608 In: The Lancet. Oncology vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	1160.	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. [electronic resource] by Dieci, M V Frassoldati, A Generali, D Bisagni, G Piacentini, F Cavanna, L Cagossi, K Puglisi, F Michelotti, A Berardi, R Banna, G Goubar, A Ficarra, G Griguolo, G Conte, Pierfranco Guarneri, V Producer: 20180219 In: Breast cancer research and treatment vol. 163 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

First
Previous
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 1590 results.